newsfilter
← Latest News
PR Newswire·

Eisai Alzheimer's Disease Pipeline Research, Including New Lecanemab (BAN2401) Data, to be Presented at 2021 Alzheimer's Association International Conference (AAIC)

WOODCLIFF LAKE, N.J., July 22, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of findings from the company's robust Alzheimer's disease (AD) pipeline, including lecanemab (BAN2401)